Sugi Predict

Sugi Predict / Compounds / SCHEMBL6474161

SCHEMBL6474161

SCHEMBL6474161

COc1c(C)cnc(CSc2ccc3ccccc3n2)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHMT2 P34897 1/20 0.51
▸ BRS3 P32247 2/20 0.50
▸ KMT2A Q03164 4/20 0.46
▸ WDR5 P61964 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ AGXT P21549 1/20 0.44
▸ PRNP P04156 6/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RXFP1 Q9HBX9 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.40
▸ PDE10A Q9Y233 1/20 0.39
▸ ATP4A P20648 2/20 0.39
▸ ATP4B P51164 2/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ RAB9A P51151 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10578851 0.76 BRS3 (0.74) SHMT2BRS3KMT2AWDR5SMN1; SMN2
SCHEMBL10866252 0.76 SHMT2 (0.49) SHMT2BRS3KMT2AWDR5L3MBTL1
SCHEMBL10867894 0.76 SHMT2 (0.72) SHMT2BRS3KMT2AWDR5L3MBTL1
SCHEMBL3379391 0.75 SHMT2 (0.48) SHMT2BRS3KMT2AWDR5AGXT
SCHEMBL10503421 0.74 BRS3 (0.56) SHMT2BRS3KMT2AWDR5SMN1; SMN2
SCHEMBL10584394 0.74 SHMT2 (0.47) SHMT2BRS3KMT2AWDR5KDM4E
Quinoline SCHEMBL8379581 0.72 SHMT2 (0.50) SHMT2BRS3KMT2AWDR5SMN1; SMN2
SCHEMBL14356330 0.71 HPGD (0.48) SHMT2BRS3KMT2AWDR5SMN1; SMN2
SCHEMBL27004025 0.70 L3MBTL1 (0.56) KMT2AL3MBTL1SMN1; SMN2PRNPMEN1
SCHEMBL10503138 0.70 BRS3 (0.52) SHMT2BRS3KMT2AWDR5SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 — — US claimed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 — — US claimed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 — — WO claimed
JP-62209062-A — — None — — JP disclosed
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 — — US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 — — US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 — — WO disclosed
JP-S62209062-A 2-PYRIDYLMETHYLTHIO-OR 2-PYRIDYLMETHYLSULFINYL-SUBSTITUTED CONDENSED RING COMPOUND YAMANOUCHI PHARMACEUT CO LTD 1987-09-14 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 SHMT2 3504/4885BRS3 1066/4885KMT2A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.